Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

A Phase IIB, Randomized, Blinded, Dose-ranging, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Dose Response Relationship of GSK1278863 Over the First 4 Weeks of Treatment and Evaluate the Safety and Efficacy of GSK1278863 Over 24 Weeks in Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Switch From Recombinant Human Erythropoietin

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01977482

Enrollment

216

Registered

2013-11-06

Start date

2013-11-01

Completion date

2015-02-06

Last updated

2018-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaemia

Keywords

hemoglobin, recombinant human erythropoietin, Chronic kidney disease, hemodialysis, pharmacokinetics, erythropoiesis stimulating agents, Anemia, GSK1278863

Brief summary

This study is intended to evaluate the dose-response relationship of GSK1278863 over the first 4 weeks of treatment and evaluate the safety and efficacy of GSK1278863 over 24 weeks to maintain hemoglobin (Hgb) level in hemodialysis-dependent (HDD) subjects with anemia associated with chronic kidney disease (CKD) who are switched from a stable dose of recombinant human erythropoietin (rhEPO). The data generated will enable selection of the starting dose(s) and optimize dose adjustment regimen(s) for Phase 3 clinical trials.

Interventions

DRUGGSK1278863

Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863

DRUGPlacebo

Matching placebo tablet for GSK1278863

DRUGrhEPO

rhEPO will be procured from local market

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* \- Subjects are eligible if they meet all of the inclusion criteria below: * General criteria * Age: \>=18 years of age. (Week -4 verification only) * Gender: Female and male subjects. (Week -4 verification only) Females: If of childbearing potential, must agree to use one of the approved contraception methods, from Screening until completion of the Follow-up Visit OR of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, hysterectomy, or oophorectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea \[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) 23.0-116.3 International units per liter (IU/L) and estradiol \<=10 picomole per liter (pmol/L) is confirmatory\]. Females on hormone replacement therapy (HRT) whose menopausal status is in doubt will be required to use one of the approved contraception methods if they wish to continue their HRT during the study. Otherwise they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment. For most forms of HRT, at least 2 weeks must elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method; * Q-T Interval Corrected for Heart Rate (QTc): Bazett's Correction of QT Interval (QTcB) \<470 millisecond (msec) or QTcB \<480 msec in subjects with bundle branch block. There is no QTc inclusion criterion for a subject with a predominantly paced rhythm. * CKD-related criteria * Dialysis frequency: On hemodialysis (HD) three to five times weekly for at least 4 weeks prior to Week -4 Screening through Week 4. NOTE: Combination methods including hemofiltration (HF) or ultrafiltration (UF) with HD are allowed. However, the type of dialysis (HD, hemodiafiltration (HDF) or UF) should not change during the study. * Dialysis adequacy: A single-pool dialyzer clearance multiplied by dialyzer time divided by volume of distribution of urea (Kt/Vurea) of \>=1.2 based on a historical value obtained within the prior month in order to ensure the adequacy of dialysis. If Kt/Vurea is not available, then an average of the last 2 values of urea reduction ratio (URR) of at least 65%. NOTE: Only needs confirming at Week -4. * Hemoglobin: Baseline Hgb of 9.0-11.5 g/dL (may rescreen in a minimum of 2 weeks). * Stable rhEPO dose: Using the same rhEPO (epoetins or their biosimilars, or darbepoetin) with total weekly doses varying by no more than 50% during the 4 weeks prior to Week -4. At Day 1 (randomization), confirm that total weekly doses varied by no more than 50% during the screening period. * Iron replacement therapy: Subjects may be on stable maintenance oral or IV (\<=100 mg/week) iron supplementation. If subjects are on oral or IV iron, then doses must be stable for the 4 weeks prior to Week -4, during the screening phase, and through the first 4 weeks after Randomization.

Exclusion criteria

* Subjects are not eligible if they meet any of the

Design outcomes

Primary

Measure	Time frame	Description
Change From Baseline in Hemoglobin (Hgb) at Week 4	Baseline (Week -4, Week-2 and Day 1) and Week 4	Baseline Hgb value was the average of three Hgb values taken during screening period at Week (W) -4, W-2 and Day 1. Change from Baseline in Hgb was calculated as W4 value minus the Baseline value. To model the dose-response relationship a four-parameter Emax model was used. The dose response dataset was based on all non-missing data collected up to W4. Participants (par.) who had a Week 2 Hgb measurement, but a missing Week 4 Hgb measurement were included with a change from Baseline at Week 4 value imputed as twice the change from Baseline at Week 2. E0 is the expected Hgb change from Baseline for a par. receiving placebo and experiencing the average Hgb Baseline observed in the study. Emax is the expected Hgb change from Baseline for a par. receiving the highest dose above which no further increase in response can be achieved. ED50 is the dose that attains the intermediate response. Gamma is the slope parameter. Alpha is the coefficient of the model covariate for centred Baseline.

Secondary

Measure	Time frame	Description
Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Week 20 to Week 24	The percentage of time in Hgb target range between Weeks 20 and 24 for a participant was calculated by dividing the total number of days that Hgb was within the target range (10.0 to 11.5 g/dL) while on treatment during Weeks 20 to 24 (using linear interpolation) by the total number of days the participant remained on treatment during the defined period. Similarly, percentage of time above Hgb target range and percentage of time below Hgb target range were calculated.
Number of Participants With Hgb in the Target Range at Week 24	Week 24	The number of participants with Hgb in the target range of 10.0 to 11.5 g/dL at Week 24 was recorded for each arm.
Number of Participants Reaching Pre-defined Hgb Stopping Criteria	Up to 24 weeks	The number of participants who reached the Hgb stopping criteria of Hgb concentration \<7.5 g/dL were presented.
Maximum Observed Change From Baseline in Erythropoietin (EPO)	Baseline (Day 1) to Week 28	Blood samples for control arm were collected on Day 1 (pre-dose), Week 4 (5-15 minutes post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 5-15 minutes post-dose), Week 24 (pre-dose), and Week 28 (pre-dose) for EPO measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose), Week 4 (7-13, 8-14, 9-15, hours post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 3 hour post-dose) Week 24 (pre-dose), and Week 28 (pre-dose) for EPO measurement. The maximum observed change from baseline in EPO was recorded for each arm. Baseline value for EPO is the pre-dose value on Day 1. Change from Baseline in EPO was calculated as the individual post-dose values minus the Baseline value.
Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)	Baseline (Day 1) to Week 28	Blood samples for control arm were collected on Day 1 (pre-dose), Week 4 (5-15 minutes post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 5-15 minutes post-dose), Week 24 (pre-dose), and Week 28 (pre-dose) for VEGF measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose), Week 4 (7-13, 8-14, 9-15, hours post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 3 hour post-dose) Week 24 (pre-dose), and Week 28 (pre-dose) for VEGF measurement. The maximum observed percent change from Baseline in VEGF was recorded for each arm. Baseline value for VEGF is the pre-dose value on Day 1. Percent change from Baseline was calculated as 100 multiplied by exponential of mean change in log scale minus 1.
Population Plasma PK Parameters of GSK1278863 and Metabolites	Day 1, Week 4, and Week 20	Blood samples were collected for individual plasma GSK1278863and metabolite (GSK2391220, GSK2499166, GSK2531403, GSK2531400, GSK2531399, and GSK2531398) concentrations measurement on Day (D) 1 (pre-dose \[PrD), at Week (W) 4 (6-12, 7-13, 8-14, and 9-15 hour \[hr\] post-dose \[PoD), and at W20 (PrD, 1, 2, and 3 hour PoD). Pharmacokinetic population: All participants from whom a PK sample has been obtained and analyzed.
Percent Change From Baseline in Hepcidin at Week 24	Baseline (Day 1) and Week 24	Hepcidin is a regulator of iron metabolism. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change from Baseline was calculated as 100 multiplied by exponential of mean change in log scale minus 1.
Change From Baseline in Ferritin at Week 24	Baseline (Day 1) and Week 24	Baseline value for ferritin is the pre-dose value on Day 1. Change from Baseline in ferritin was calculated as the Week 24 value minus the Baseline value.
Hgb Concentration at Week 24	Week 24	Hgb values measured at Week 24 are presented.
Percent Change From Baseline in Transferrin Saturation at Week 24	Baseline (Day 1) and Week 24	Transferrin saturation is measured as a percentage, it is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change from Baseline =: 100\*(exp(Mean change log scale)-1).
Change From Baseline in Total Iron at Week 24	Baseline (Day 1) and Week 24	Baseline value for total iron is the pre-dose value on Day 1. Change from Baseline in total iron was calculated as the Week 24 value minus the Baseline value.
Change From Baseline in Total Iron Binding Capacity at Week 24	Baseline (Day 1) and Week 24	Total iron-binding capacity is a medical laboratory test that measures the blood's capacity to bind iron with transferrin. Baseline value for total iron binding capacity is the pre-dose value on Day 1. Change from Baseline in total iron binding capacity was calculated as the Week 24 value minus the Baseline value.
Change From Baseline in Reticulocyte Hemoglobin at Week 24	Baseline (Day 1) and Week 24	Baseline value for reticulocyte hemoglobin is the pre-dose value on Day 1. Change from Baseline in reticulocyte hemoglobin was calculated as the Week 24 value minus the Baseline value.
Change From Baseline in Hematocrit at Week 24	Baseline (Day 1) and Week 24	Hematocrit is the ratio of the volume of red blood cells to the total volume of blood. Baseline value for hematocrit is the pre-dose value on Day 1. Change from Baseline in hematocrit was calculated as the Week 24 value minus the Baseline value.
Change From Baseline in Red Blood Cells at Week 24	Baseline (Day 1) and Week 24	Baseline value for red blood cells is the pre-dose value on Day 1. Change from Baseline in red blood cells was calculated as the Week 24 value minus the Baseline value.
Change From Baseline in Reticulocyte Count at Week 24	Baseline (Day 1) and Week 24	A reticulocyte count is a blood test that measures the percentage of reticulocytes in the blood. Reticulocytes are slightly immature red blood cells. Baseline value for reticulocyte count is the pre-dose value on Day 1. Change from Baseline in reticulocyte count was calculated as the Week 24 value minus the Baseline value.
Change From Baseline in Transferrin at Week 24	Baseline (Day 1) and Week 24	Baseline value for transferrin is the pre-dose value on Day 1. Change from Baseline in transferrin was calculated as the Week 24 value minus the Baseline value.

Countries

Australia, Canada, Czechia, Denmark, France, Germany, Hungary, Japan, Norway, Poland, Russia, South Korea, Spain, Sweden, United Kingdom, United States

Participant flow

Recruitment details

Eligible participants were hemodialysis-dependent with anemia associated with chronic kidney disease who were switched from a stable dose of recombinant human erythropoietin (rhEPO).

Pre-assignment details

A total of 216 participants with a stable hemoglobin (Hgb) between 9.0-11.5 grams (g)/deciliter (dL) (France sites only: 10.0-11.5 g/dL) were randomized.

Participants by arm

Arm	Count
Control Participants received placebo once daily for the first 4 weeks and thereafter received open label rhEPO as required to achieve Hgb within the range of 10.0-11.5 g/dL for the remaining 20 weeks.	39
GSK1278863 4 mg Participants received GSK1278863 4 mg once daily for the first 4 weeks and thereafter, if necessary the dose was adjusted every four weeks to achieve Hgb within the range of 10.0-11.5 g/dL for the remaining 20 weeks.	39
GSK1278863 6 mg Participants received GSK1278863 6 mg once daily for the first 4 weeks and thereafter, if necessary the dose was adjusted every four weeks to achieve Hgb within the range of 10.0-11.5 g/dL for the remaining 20 weeks.	40
GSK1278863 8 mg Participants received GSK1278863 8 mg once daily for the first 4 weeks and thereafter, if necessary the dose was adjusted every four weeks to achieve Hgb within the range of 10.0-11.5 g/dL for the remaining 20 weeks.	39
GSK1278863 10 mg Participants received GSK1278863 10 mg once daily for the first 4 weeks and thereafter, if necessary the dose was adjusted every four weeks to achieve Hgb within the range of 10.0-11.5 g/dL for the remaining 20 weeks.	40
GSK1278863 12 mg Participants received GSK1278863 12 mg once daily for the first 4 weeks and thereafter, if necessary the dose was adjusted every four weeks to achieve Hgb within the range of 10.0-11.5 g/dL for the remaining 20 weeks.	19
Total	216

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005
Overall Study	Adverse Event	0	1	1	0	2	0
Overall Study	Lost to Follow-up	1	0	0	0	0	0
Overall Study	Other-Protocol-defined Stopping Criteria	0	3	2	1	0	0
Overall Study	Physician Decision	0	1	0	0	0	0
Overall Study	Protocol Violation	0	0	1	0	0	0
Overall Study	Withdrawal by Subject	2	4	1	3	1	5

Baseline characteristics

Characteristic	Control	GSK1278863 4 mg	GSK1278863 6 mg	GSK1278863 8 mg	GSK1278863 10 mg	GSK1278863 12 mg	Total
Age, Continuous Years	59.7 Years STANDARD_DEVIATION 18.74	58.7 Years STANDARD_DEVIATION 13.33	63.5 Years STANDARD_DEVIATION 14	60.1 Years STANDARD_DEVIATION 10.36	55.4 Years STANDARD_DEVIATION 15.5	59.9 Years STANDARD_DEVIATION 13.26	59.5 Years STANDARD_DEVIATION 14.58
Race/Ethnicity, Customized African American	7 Participants	4 Participants	5 Participants	3 Participants	4 Participants	4 Participants	27 Participants
Race/Ethnicity, Customized Asian	7 Participants	6 Participants	7 Participants	7 Participants	5 Participants	3 Participants	35 Participants
Race/Ethnicity, Customized Other	2 Participants	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants	4 Participants
Race/Ethnicity, Customized White	23 Participants	28 Participants	28 Participants	28 Participants	31 Participants	12 Participants	150 Participants
Sex: Female, Male Female	13 Participants	15 Participants	12 Participants	15 Participants	17 Participants	8 Participants	80 Participants
Sex: Female, Male Male	26 Participants	24 Participants	28 Participants	24 Participants	23 Participants	11 Participants	136 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —	— / —	— / —	— / —
other Total, other adverse events	17 / 39	28 / 39	17 / 40	25 / 39	21 / 40	6 / 19
serious Total, serious adverse events	11 / 39	10 / 39	8 / 40	8 / 39	11 / 40	1 / 19

Outcome results

Primary

Change From Baseline in Hemoglobin (Hgb) at Week 4

Baseline Hgb value was the average of three Hgb values taken during screening period at Week (W) -4, W-2 and Day 1. Change from Baseline in Hgb was calculated as W4 value minus the Baseline value. To model the dose-response relationship a four-parameter Emax model was used. The dose response dataset was based on all non-missing data collected up to W4. Participants (par.) who had a Week 2 Hgb measurement, but a missing Week 4 Hgb measurement were included with a change from Baseline at Week 4 value imputed as twice the change from Baseline at Week 2. E0 is the expected Hgb change from Baseline for a par. receiving placebo and experiencing the average Hgb Baseline observed in the study. Emax is the expected Hgb change from Baseline for a par. receiving the highest dose above which no further increase in response can be achieved. ED50 is the dose that attains the intermediate response. Gamma is the slope parameter. Alpha is the coefficient of the model covariate for centred Baseline.

Time frame: Baseline (Week -4, Week-2 and Day 1) and Week 4

Population: ITT Population. Only participants with data available at specific time point were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
Control	Change From Baseline in Hemoglobin (Hgb) at Week 4	-0.64 grams (g)/deciliter (dL)	Standard Deviation 0.829
GSK1278863 4 mg	Change From Baseline in Hemoglobin (Hgb) at Week 4	-0.24 grams (g)/deciliter (dL)	Standard Deviation 0.989
GSK1278863 6 mg	Change From Baseline in Hemoglobin (Hgb) at Week 4	0.08 grams (g)/deciliter (dL)	Standard Deviation 1.131
GSK1278863 8 mg	Change From Baseline in Hemoglobin (Hgb) at Week 4	0.42 grams (g)/deciliter (dL)	Standard Deviation 0.796
GSK1278863 10 mg	Change From Baseline in Hemoglobin (Hgb) at Week 4	0.64 grams (g)/deciliter (dL)	Standard Deviation 1.177
GSK1278863 12 mg	Change From Baseline in Hemoglobin (Hgb) at Week 4	0.61 grams (g)/deciliter (dL)	Standard Deviation 1.245

95% CI: [-0.96, -0.387]

95% CI: [15.566, 48.948]

95% CI: [2.691, 7.94]

95% CI: [0.748, 1.738]

95% CI: [0.84, 1.234]

95% CI: [-0.397, -0.014]

95% CI: [0, 2.342]

95% CI: [0, 4.15]

95% CI: [2.544, 5.995]

95% CI: [4.698, 8.01]

95% CI: [6.931, 10.523]

95% CI: [9.024, 14.004]

95% CI: [10.891, 18.916]

Secondary

Change From Baseline in Ferritin at Week 24

Baseline value for ferritin is the pre-dose value on Day 1. Change from Baseline in ferritin was calculated as the Week 24 value minus the Baseline value.

Time frame: Baseline (Day 1) and Week 24

Population: ITT Population. Only participants with data available at specific time point were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
Control	Change From Baseline in Ferritin at Week 24	56.8 Micrograms/Liter	Standard Deviation 214.27
GSK1278863 4 mg	Change From Baseline in Ferritin at Week 24	-29.4 Micrograms/Liter	Standard Deviation 357.1
GSK1278863 6 mg	Change From Baseline in Ferritin at Week 24	-50.4 Micrograms/Liter	Standard Deviation 408.99
GSK1278863 8 mg	Change From Baseline in Ferritin at Week 24	-95.6 Micrograms/Liter	Standard Deviation 304.61
GSK1278863 10 mg	Change From Baseline in Ferritin at Week 24	-20.2 Micrograms/Liter	Standard Deviation 227.34
GSK1278863 12 mg	Change From Baseline in Ferritin at Week 24	-125.2 Micrograms/Liter	Standard Deviation 354.64

Secondary

Change From Baseline in Hematocrit at Week 24

Hematocrit is the ratio of the volume of red blood cells to the total volume of blood. Baseline value for hematocrit is the pre-dose value on Day 1. Change from Baseline in hematocrit was calculated as the Week 24 value minus the Baseline value.

Time frame: Baseline (Day 1) and Week 24

Population: ITT Population. Only participants with data available at specific time point were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
Control	Change From Baseline in Hematocrit at Week 24	-0.0028 Ratio	Standard Deviation 0.04358
GSK1278863 4 mg	Change From Baseline in Hematocrit at Week 24	-0.0096 Ratio	Standard Deviation 0.04073
GSK1278863 6 mg	Change From Baseline in Hematocrit at Week 24	0.0020 Ratio	Standard Deviation 0.03579
GSK1278863 8 mg	Change From Baseline in Hematocrit at Week 24	0.0043 Ratio	Standard Deviation 0.04254
GSK1278863 10 mg	Change From Baseline in Hematocrit at Week 24	-0.0021 Ratio	Standard Deviation 0.02678
GSK1278863 12 mg	Change From Baseline in Hematocrit at Week 24	0.0108 Ratio	Standard Deviation 0.03557

Secondary

Change From Baseline in Red Blood Cells at Week 24

Baseline value for red blood cells is the pre-dose value on Day 1. Change from Baseline in red blood cells was calculated as the Week 24 value minus the Baseline value.

Time frame: Baseline (Day 1) and Week 24

Population: ITT Population. Only participants with data available at specific time point were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
Control	Change From Baseline in Red Blood Cells at Week 24	0.01 10^12 cells/Liter	Standard Deviation 0.46
GSK1278863 4 mg	Change From Baseline in Red Blood Cells at Week 24	-0.06 10^12 cells/Liter	Standard Deviation 0.396
GSK1278863 6 mg	Change From Baseline in Red Blood Cells at Week 24	0.04 10^12 cells/Liter	Standard Deviation 0.374
GSK1278863 8 mg	Change From Baseline in Red Blood Cells at Week 24	0.07 10^12 cells/Liter	Standard Deviation 0.399
GSK1278863 10 mg	Change From Baseline in Red Blood Cells at Week 24	0.03 10^12 cells/Liter	Standard Deviation 0.3
GSK1278863 12 mg	Change From Baseline in Red Blood Cells at Week 24	0.17 10^12 cells/Liter	Standard Deviation 0.366

Secondary

Change From Baseline in Reticulocyte Count at Week 24

A reticulocyte count is a blood test that measures the percentage of reticulocytes in the blood. Reticulocytes are slightly immature red blood cells. Baseline value for reticulocyte count is the pre-dose value on Day 1. Change from Baseline in reticulocyte count was calculated as the Week 24 value minus the Baseline value.

Time frame: Baseline (Day 1) and Week 24

Population: ITT Population. Only participants with data available at specific time point were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
Control	Change From Baseline in Reticulocyte Count at Week 24	0.40 Percentage of reticulocytes in blood	Standard Deviation 0.663
GSK1278863 4 mg	Change From Baseline in Reticulocyte Count at Week 24	0.16 Percentage of reticulocytes in blood	Standard Deviation 1.162
GSK1278863 6 mg	Change From Baseline in Reticulocyte Count at Week 24	0.18 Percentage of reticulocytes in blood	Standard Deviation 0.571
GSK1278863 8 mg	Change From Baseline in Reticulocyte Count at Week 24	0.03 Percentage of reticulocytes in blood	Standard Deviation 0.684
GSK1278863 10 mg	Change From Baseline in Reticulocyte Count at Week 24	-0.15 Percentage of reticulocytes in blood	Standard Deviation 0.838
GSK1278863 12 mg	Change From Baseline in Reticulocyte Count at Week 24	0.10 Percentage of reticulocytes in blood	Standard Deviation 0.527

Secondary

Change From Baseline in Reticulocyte Hemoglobin at Week 24

Baseline value for reticulocyte hemoglobin is the pre-dose value on Day 1. Change from Baseline in reticulocyte hemoglobin was calculated as the Week 24 value minus the Baseline value.

Time frame: Baseline (Day 1) and Week 24

Population: ITT Population. Only participants with data available at specific time point were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
Control	Change From Baseline in Reticulocyte Hemoglobin at Week 24	-0.19 Picogram	Standard Deviation 1.61
GSK1278863 4 mg	Change From Baseline in Reticulocyte Hemoglobin at Week 24	-0.28 Picogram	Standard Deviation 1.948
GSK1278863 6 mg	Change From Baseline in Reticulocyte Hemoglobin at Week 24	-0.62 Picogram	Standard Deviation 2.046
GSK1278863 8 mg	Change From Baseline in Reticulocyte Hemoglobin at Week 24	-0.42 Picogram	Standard Deviation 1.458
GSK1278863 10 mg	Change From Baseline in Reticulocyte Hemoglobin at Week 24	-0.51 Picogram	Standard Deviation 1.377
GSK1278863 12 mg	Change From Baseline in Reticulocyte Hemoglobin at Week 24	-0.63 Picogram	Standard Deviation 1.119

Secondary

Change From Baseline in Total Iron at Week 24

Baseline value for total iron is the pre-dose value on Day 1. Change from Baseline in total iron was calculated as the Week 24 value minus the Baseline value.

Time frame: Baseline (Day 1) and Week 24

Population: ITT Population. Only participants with data available at specific time point were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
Control	Change From Baseline in Total Iron at Week 24	-0.8 Micromoles/Liter	Standard Deviation 7.64
GSK1278863 4 mg	Change From Baseline in Total Iron at Week 24	0.9 Micromoles/Liter	Standard Deviation 9.75
GSK1278863 6 mg	Change From Baseline in Total Iron at Week 24	0.3 Micromoles/Liter	Standard Deviation 5.2
GSK1278863 8 mg	Change From Baseline in Total Iron at Week 24	0.2 Micromoles/Liter	Standard Deviation 6.51
GSK1278863 10 mg	Change From Baseline in Total Iron at Week 24	2.0 Micromoles/Liter	Standard Deviation 3.96
GSK1278863 12 mg	Change From Baseline in Total Iron at Week 24	1.6 Micromoles/Liter	Standard Deviation 3.18

Secondary

Change From Baseline in Total Iron Binding Capacity at Week 24

Total iron-binding capacity is a medical laboratory test that measures the blood's capacity to bind iron with transferrin. Baseline value for total iron binding capacity is the pre-dose value on Day 1. Change from Baseline in total iron binding capacity was calculated as the Week 24 value minus the Baseline value.

Time frame: Baseline (Day 1) and Week 24

Population: ITT Population. Only participants with data available at specific time point were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
Control	Change From Baseline in Total Iron Binding Capacity at Week 24	-2.0 Micromoles/Liter	Standard Deviation 4.48
GSK1278863 4 mg	Change From Baseline in Total Iron Binding Capacity at Week 24	6.0 Micromoles/Liter	Standard Deviation 7.93
GSK1278863 6 mg	Change From Baseline in Total Iron Binding Capacity at Week 24	4.2 Micromoles/Liter	Standard Deviation 6.79
GSK1278863 8 mg	Change From Baseline in Total Iron Binding Capacity at Week 24	6.6 Micromoles/Liter	Standard Deviation 5.75
GSK1278863 10 mg	Change From Baseline in Total Iron Binding Capacity at Week 24	4.8 Micromoles/Liter	Standard Deviation 6.25
GSK1278863 12 mg	Change From Baseline in Total Iron Binding Capacity at Week 24	6.2 Micromoles/Liter	Standard Deviation 6.44

Secondary

Change From Baseline in Transferrin at Week 24

Baseline value for transferrin is the pre-dose value on Day 1. Change from Baseline in transferrin was calculated as the Week 24 value minus the Baseline value.

Time frame: Baseline (Day 1) and Week 24

Population: ITT Population. Only participants with data available at specific time point were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
Control	Change From Baseline in Transferrin at Week 24	-0.133 grams (g)/Liter (L)	Standard Deviation 0.2903
GSK1278863 4 mg	Change From Baseline in Transferrin at Week 24	0.238 grams (g)/Liter (L)	Standard Deviation 0.3709
GSK1278863 6 mg	Change From Baseline in Transferrin at Week 24	0.198 grams (g)/Liter (L)	Standard Deviation 0.2891
GSK1278863 8 mg	Change From Baseline in Transferrin at Week 24	0.226 grams (g)/Liter (L)	Standard Deviation 0.2706
GSK1278863 10 mg	Change From Baseline in Transferrin at Week 24	0.249 grams (g)/Liter (L)	Standard Deviation 0.3213
GSK1278863 12 mg	Change From Baseline in Transferrin at Week 24	0.393 grams (g)/Liter (L)	Standard Deviation 0.3165

Secondary

Hgb Concentration at Week 24

Hgb values measured at Week 24 are presented.

Time frame: Week 24

Population: ITT Population. Only participants with data available at specific time point were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
Control	Hgb Concentration at Week 24	10.56 g/dL	Standard Deviation 0.974
GSK1278863 4 mg	Hgb Concentration at Week 24	10.29 g/dL	Standard Deviation 0.864
GSK1278863 6 mg	Hgb Concentration at Week 24	10.54 g/dL	Standard Deviation 1.01
GSK1278863 8 mg	Hgb Concentration at Week 24	10.63 g/dL	Standard Deviation 1.099
GSK1278863 10 mg	Hgb Concentration at Week 24	10.28 g/dL	Standard Deviation 0.856
GSK1278863 12 mg	Hgb Concentration at Week 24	10.70 g/dL	Standard Deviation 0.867

Secondary

Maximum Observed Change From Baseline in Erythropoietin (EPO)

Blood samples for control arm were collected on Day 1 (pre-dose), Week 4 (5-15 minutes post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 5-15 minutes post-dose), Week 24 (pre-dose), and Week 28 (pre-dose) for EPO measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose), Week 4 (7-13, 8-14, 9-15, hours post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 3 hour post-dose) Week 24 (pre-dose), and Week 28 (pre-dose) for EPO measurement. The maximum observed change from baseline in EPO was recorded for each arm. Baseline value for EPO is the pre-dose value on Day 1. Change from Baseline in EPO was calculated as the individual post-dose values minus the Baseline value.

Time frame: Baseline (Day 1) to Week 28

Population: ITT Population. Only participants with data available at specific time point were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
Control	Maximum Observed Change From Baseline in Erythropoietin (EPO)	1946.45 international units(IU)/Liter (L)	Standard Deviation 8456.313
GSK1278863 4 mg	Maximum Observed Change From Baseline in Erythropoietin (EPO)	48.86 international units(IU)/Liter (L)	Standard Deviation 117.05
GSK1278863 6 mg	Maximum Observed Change From Baseline in Erythropoietin (EPO)	36.63 international units(IU)/Liter (L)	Standard Deviation 35.485
GSK1278863 8 mg	Maximum Observed Change From Baseline in Erythropoietin (EPO)	84.53 international units(IU)/Liter (L)	Standard Deviation 225.768
GSK1278863 10 mg	Maximum Observed Change From Baseline in Erythropoietin (EPO)	82.00 international units(IU)/Liter (L)	Standard Deviation 99.66
GSK1278863 12 mg	Maximum Observed Change From Baseline in Erythropoietin (EPO)	24.63 international units(IU)/Liter (L)	Standard Deviation 235.82

Secondary

Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)

Blood samples for control arm were collected on Day 1 (pre-dose), Week 4 (5-15 minutes post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 5-15 minutes post-dose), Week 24 (pre-dose), and Week 28 (pre-dose) for VEGF measurement. Blood samples for GSK1278863 arms were collected on Day 1 (pre-dose), Week 4 (6-12 hours post-dose), Week 4 (7-13, 8-14, 9-15, hours post-dose), Week 8 (pre-dose), Week 12 (pre-dose), Week 16 (pre-dose), Week 20 (pre-dose, 3 hour post-dose) Week 24 (pre-dose), and Week 28 (pre-dose) for VEGF measurement. The maximum observed percent change from Baseline in VEGF was recorded for each arm. Baseline value for VEGF is the pre-dose value on Day 1. Percent change from Baseline was calculated as 100 multiplied by exponential of mean change in log scale minus 1.

Time frame: Baseline (Day 1) to Week 28

Population: ITT Population. Only participants with data available at specific time point were analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)
Control	Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)	36.02 Percent change
GSK1278863 4 mg	Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)	36.92 Percent change
GSK1278863 6 mg	Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)	41.73 Percent change
GSK1278863 8 mg	Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)	54.91 Percent change
GSK1278863 10 mg	Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)	50.65 Percent change
GSK1278863 12 mg	Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)	50.97 Percent change

Secondary

Number of Participants Reaching Pre-defined Hgb Stopping Criteria

The number of participants who reached the Hgb stopping criteria of Hgb concentration \<7.5 g/dL were presented.

Time frame: Up to 24 weeks

Population: ITT Population

Arm	Measure	Value (NUMBER)
Control	Number of Participants Reaching Pre-defined Hgb Stopping Criteria	0 Participants
GSK1278863 4 mg	Number of Participants Reaching Pre-defined Hgb Stopping Criteria	0 Participants
GSK1278863 6 mg	Number of Participants Reaching Pre-defined Hgb Stopping Criteria	0 Participants
GSK1278863 8 mg	Number of Participants Reaching Pre-defined Hgb Stopping Criteria	0 Participants
GSK1278863 10 mg	Number of Participants Reaching Pre-defined Hgb Stopping Criteria	0 Participants
GSK1278863 12 mg	Number of Participants Reaching Pre-defined Hgb Stopping Criteria	0 Participants

Secondary

Number of Participants With Hgb in the Target Range at Week 24

The number of participants with Hgb in the target range of 10.0 to 11.5 g/dL at Week 24 was recorded for each arm.

Time frame: Week 24

Population: ITT Population. Only participants with data available at specific time point were analyzed.

Arm	Measure	Value (NUMBER)
Control	Number of Participants With Hgb in the Target Range at Week 24	14 Participants
GSK1278863 4 mg	Number of Participants With Hgb in the Target Range at Week 24	13 Participants
GSK1278863 6 mg	Number of Participants With Hgb in the Target Range at Week 24	16 Participants
GSK1278863 8 mg	Number of Participants With Hgb in the Target Range at Week 24	10 Participants
GSK1278863 10 mg	Number of Participants With Hgb in the Target Range at Week 24	15 Participants
GSK1278863 12 mg	Number of Participants With Hgb in the Target Range at Week 24	8 Participants

Secondary

Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24

The percentage of time in Hgb target range between Weeks 20 and 24 for a participant was calculated by dividing the total number of days that Hgb was within the target range (10.0 to 11.5 g/dL) while on treatment during Weeks 20 to 24 (using linear interpolation) by the total number of days the participant remained on treatment during the defined period. Similarly, percentage of time above Hgb target range and percentage of time below Hgb target range were calculated.

Time frame: Week 20 to Week 24

Population: ITT population. Only participants with data available at specific timepoint were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
Control	Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Percentage of time above target range	24.65 Percentage of days	Standard Deviation 38.556
Control	Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Percentage of time within target range	54.59 Percentage of days	Standard Deviation 42.044
Control	Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Percentage of time below target range	20.76 Percentage of days	Standard Deviation 36.587
GSK1278863 4 mg	Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Percentage of time above target range	6.89 Percentage of days	Standard Deviation 22.137
GSK1278863 4 mg	Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Percentage of time within target range	74.77 Percentage of days	Standard Deviation 38.797
GSK1278863 4 mg	Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Percentage of time below target range	18.34 Percentage of days	Standard Deviation 35.778
GSK1278863 6 mg	Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Percentage of time above target range	17.18 Percentage of days	Standard Deviation 30.446
GSK1278863 6 mg	Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Percentage of time within target range	57.38 Percentage of days	Standard Deviation 40.505
GSK1278863 6 mg	Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Percentage of time below target range	25.44 Percentage of days	Standard Deviation 40.12
GSK1278863 8 mg	Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Percentage of time above target range	33.15 Percentage of days	Standard Deviation 42.856
GSK1278863 8 mg	Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Percentage of time within target range	37.46 Percentage of days	Standard Deviation 41.775
GSK1278863 8 mg	Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Percentage of time below target range	29.39 Percentage of days	Standard Deviation 42.67
GSK1278863 10 mg	Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Percentage of time above target range	18.27 Percentage of days	Standard Deviation 33.698
GSK1278863 10 mg	Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Percentage of time within target range	48.97 Percentage of days	Standard Deviation 42.49
GSK1278863 10 mg	Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Percentage of time below target range	32.76 Percentage of days	Standard Deviation 43.78
GSK1278863 12 mg	Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Percentage of time within target range	55.23 Percentage of days	Standard Deviation 40.35
GSK1278863 12 mg	Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Percentage of time below target range	17.89 Percentage of days	Standard Deviation 36.836
GSK1278863 12 mg	Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24	Percentage of time above target range	26.88 Percentage of days	Standard Deviation 36.154

Secondary

Percent Change From Baseline in Hepcidin at Week 24

Hepcidin is a regulator of iron metabolism. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change from Baseline was calculated as 100 multiplied by exponential of mean change in log scale minus 1.

Time frame: Baseline (Day 1) and Week 24

Population: ITT Population. Only participants with data available at specific time point were analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)
Control	Percent Change From Baseline in Hepcidin at Week 24	3.63 Percent change
GSK1278863 4 mg	Percent Change From Baseline in Hepcidin at Week 24	-17.39 Percent change
GSK1278863 6 mg	Percent Change From Baseline in Hepcidin at Week 24	-11.85 Percent change
GSK1278863 8 mg	Percent Change From Baseline in Hepcidin at Week 24	-30.28 Percent change
GSK1278863 10 mg	Percent Change From Baseline in Hepcidin at Week 24	-6.91 Percent change
GSK1278863 12 mg	Percent Change From Baseline in Hepcidin at Week 24	-42.13 Percent change

Secondary

Percent Change From Baseline in Transferrin Saturation at Week 24

Transferrin saturation is measured as a percentage, it is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value for transferrin saturation is the pre-dose value on Day 1. Percent change from Baseline =: 100\*(exp(Mean change log scale)-1).

Time frame: Baseline (Day 1) and Week 24

Population: ITT Population. Only participants with data available at specific time point were analyzed.

Arm	Measure	Value (GEOMETRIC_MEAN)
Control	Percent Change From Baseline in Transferrin Saturation at Week 24	-9.0 Percent change
GSK1278863 4 mg	Percent Change From Baseline in Transferrin Saturation at Week 24	-3.7 Percent change
GSK1278863 6 mg	Percent Change From Baseline in Transferrin Saturation at Week 24	-12.1 Percent change
GSK1278863 8 mg	Percent Change From Baseline in Transferrin Saturation at Week 24	-8.3 Percent change
GSK1278863 10 mg	Percent Change From Baseline in Transferrin Saturation at Week 24	8.2 Percent change
GSK1278863 12 mg	Percent Change From Baseline in Transferrin Saturation at Week 24	-2.5 Percent change

Secondary

Population Plasma PK Parameters of GSK1278863 and Metabolites

Blood samples were collected for individual plasma GSK1278863and metabolite (GSK2391220, GSK2499166, GSK2531403, GSK2531400, GSK2531399, and GSK2531398) concentrations measurement on Day (D) 1 (pre-dose \[PrD), at Week (W) 4 (6-12, 7-13, 8-14, and 9-15 hour \[hr\] post-dose \[PoD), and at W20 (PrD, 1, 2, and 3 hour PoD). Pharmacokinetic population: All participants from whom a PK sample has been obtained and analyzed.

Time frame: Day 1, Week 4, and Week 20

Population: Pharmacokinetic Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed at different time points; thus, the overall number of participants analyzed reflects everyone in the pharmacokinetic population

Arm	Measure	Group	Value (MEAN)	Dispersion
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	6.3 nanograms (ng)/milliliter (mL)	Standard Deviation 4.84
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, PrD, n=23, 28, 27, 23, 14	7.7 nanograms (ng)/milliliter (mL)	Standard Deviation 7.71
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	3.3 nanograms (ng)/milliliter (mL)	Standard Deviation 3.76
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, 2 hr PoD, n=23, 27, 27, 24, 13	34.2 nanograms (ng)/milliliter (mL)	Standard Deviation 31.76
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, 1 hr PoD, n=23, 27, 27, 24, 13	4.9 nanograms (ng)/milliliter (mL)	Standard Deviation 5.56
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	1.8 nanograms (ng)/milliliter (mL)	Standard Deviation 1.31
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	3.3 nanograms (ng)/milliliter (mL)	Standard Deviation 3.36
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, PrD, n=23, 28, 27, 23, 14	5.0 nanograms (ng)/milliliter (mL)	Standard Deviation 7.72
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	3.4 nanograms (ng)/milliliter (mL)	Standard Deviation 2.46
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	7.5 nanograms (ng)/milliliter (mL)	Standard Deviation 16.8
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, 1 hr PoD, n=23, 27, 27, 24, 13	25.9 nanograms (ng)/milliliter (mL)	Standard Deviation 35.74
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	4.0 nanograms (ng)/milliliter (mL)	Standard Deviation 3.63
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, 1 hr PoD, n=23, 27, 27, 24, 13	3.9 nanograms (ng)/milliliter (mL)	Standard Deviation 5.59
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	11.4 nanograms (ng)/milliliter (mL)	Standard Deviation 7.47
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, 3 hr PoD, n=23, 27, 27, 24, 14	43.6 nanograms (ng)/milliliter (mL)	Standard Deviation 58.36
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	5.4 nanograms (ng)/milliliter (mL)	Standard Deviation 4.49
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, 2 hr PoD, n=23, 27, 27, 24, 13	5.4 nanograms (ng)/milliliter (mL)	Standard Deviation 5.58
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, 2 hr PoD, n=23, 27, 27, 24, 13	5.7 nanograms (ng)/milliliter (mL)	Standard Deviation 5.43
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, 3 hr PoD, n=23, 27, 27, 24, 14	5.5 nanograms (ng)/milliliter (mL)	Standard Deviation 4.52
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, 1 hr PoD, n=23, 27, 27, 24, 13	1.4 nanograms (ng)/milliliter (mL)	Standard Deviation 1.27
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	9.9 nanograms (ng)/milliliter (mL)	Standard Deviation 8
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, 3 hr PoD, n=23, 27, 27, 24, 14	5.3 nanograms (ng)/milliliter (mL)	Standard Deviation 4.64
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	1.3 nanograms (ng)/milliliter (mL)	Standard Deviation 1.07
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	10.6 nanograms (ng)/milliliter (mL)	Standard Deviation 25.15
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, PrD, n=23, 28, 27, 23, 14	7.8 nanograms (ng)/milliliter (mL)	Standard Deviation 8.53
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	1.1 nanograms (ng)/milliliter (mL)	Standard Deviation 1.16
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, 3 hr PoD, n=23, 27, 27, 24, 14	2.3 nanograms (ng)/milliliter (mL)	Standard Deviation 2.04
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	3.1 nanograms (ng)/milliliter (mL)	Standard Deviation 2.82
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, 3 hr PoD, n=23, 27, 27, 24, 14	4.1 nanograms (ng)/milliliter (mL)	Standard Deviation 4.07
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	6.8 nanograms (ng)/milliliter (mL)	Standard Deviation 14.53
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	9.1 nanograms (ng)/milliliter (mL)	Standard Deviation 6.68
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, 2 hr PoD, n=23, 27, 27, 24, 13	2.1 nanograms (ng)/milliliter (mL)	Standard Deviation 2.24
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	1.8 nanograms (ng)/milliliter (mL)	Standard Deviation 1.75
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, 3 hr PoD, n=23, 27, 27, 24, 14	1.4 nanograms (ng)/milliliter (mL)	Standard Deviation 1.12
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	3.2 nanograms (ng)/milliliter (mL)	Standard Deviation 1.98
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, 1 hr PoD, n=23, 27, 27, 24, 13	1.3 nanograms (ng)/milliliter (mL)	Standard Deviation 1.89
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	1.5 nanograms (ng)/milliliter (mL)	Standard Deviation 1.67
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, 2 hr PoD, n=23, 27, 27, 24, 13	4.2 nanograms (ng)/milliliter (mL)	Standard Deviation 4.44
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	6.3 nanograms (ng)/milliliter (mL)	Standard Deviation 10.04
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	5.1 nanograms (ng)/milliliter (mL)	Standard Deviation 4.22
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, PrD, n=23, 28, 27, 23, 14	1.5 nanograms (ng)/milliliter (mL)	Standard Deviation 2.31
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	1.4 nanograms (ng)/milliliter (mL)	Standard Deviation 1.88
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, PrD, n=23, 28, 27, 23, 14	2.3 nanograms (ng)/milliliter (mL)	Standard Deviation 1.99
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	4.7 nanograms (ng)/milliliter (mL)	Standard Deviation 4.23
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	1.4 nanograms (ng)/milliliter (mL)	Standard Deviation 1.58
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, PrD, n=23, 28, 27, 23, 14	1.2 nanograms (ng)/milliliter (mL)	Standard Deviation 3.38
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, 1 hr PoD, n=23, 27, 27, 24, 13	4.2 nanograms (ng)/milliliter (mL)	Standard Deviation 4.52
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	4.1 nanograms (ng)/milliliter (mL)	Standard Deviation 4.6
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	3.8 nanograms (ng)/milliliter (mL)	Standard Deviation 3.66
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	1.5 nanograms (ng)/milliliter (mL)	Standard Deviation 1.46
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, 1 hr PoD, n=23, 27, 27, 24, 13	2.0 nanograms (ng)/milliliter (mL)	Standard Deviation 3.82
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, 3 hr PoD, n=23, 27, 27, 24, 14	3.9 nanograms (ng)/milliliter (mL)	Standard Deviation 3.49
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, PrD, n=23, 28, 27, 23, 14	2.3 nanograms (ng)/milliliter (mL)	Standard Deviation 6.44
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, 2 hr PoD, n=23, 27, 27, 24, 13	1.5 nanograms (ng)/milliliter (mL)	Standard Deviation 1.25
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	2.0 nanograms (ng)/milliliter (mL)	Standard Deviation 1.72
Control	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, 2 hr PoD, n=23, 27, 27, 24, 13	3.8 nanograms (ng)/milliliter (mL)	Standard Deviation 4.58
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	7.1 nanograms (ng)/milliliter (mL)	Standard Deviation 5.53
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, PrD, n=23, 28, 27, 23, 14	0.7 nanograms (ng)/milliliter (mL)	Standard Deviation 2.55
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	4.9 nanograms (ng)/milliliter (mL)	Standard Deviation 3.11
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, 3 hr PoD, n=23, 27, 27, 24, 14	4.3 nanograms (ng)/milliliter (mL)	Standard Deviation 4.76
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	9.3 nanograms (ng)/milliliter (mL)	Standard Deviation 19.06
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	5.7 nanograms (ng)/milliliter (mL)	Standard Deviation 4.63
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, 3 hr PoD, n=23, 27, 27, 24, 14	1.3 nanograms (ng)/milliliter (mL)	Standard Deviation 1.26
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	4.9 nanograms (ng)/milliliter (mL)	Standard Deviation 2.68
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, 2 hr PoD, n=23, 27, 27, 24, 13	1.2 nanograms (ng)/milliliter (mL)	Standard Deviation 1.24
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	2.5 nanograms (ng)/milliliter (mL)	Standard Deviation 1.71
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, 1 hr PoD, n=23, 27, 27, 24, 13	1.1 nanograms (ng)/milliliter (mL)	Standard Deviation 1.4
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	1.6 nanograms (ng)/milliliter (mL)	Standard Deviation 1.16
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, 1 hr PoD, n=23, 27, 27, 24, 13	37.6 nanograms (ng)/milliliter (mL)	Standard Deviation 53.77
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, PrD, n=23, 28, 27, 23, 14	1.9 nanograms (ng)/milliliter (mL)	Standard Deviation 2.05
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	1.2 nanograms (ng)/milliliter (mL)	Standard Deviation 0.88
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	8.6 nanograms (ng)/milliliter (mL)	Standard Deviation 6.43
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, 2 hr PoD, n=23, 27, 27, 24, 13	52.4 nanograms (ng)/milliliter (mL)	Standard Deviation 53.32
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, 2 hr PoD, n=23, 27, 27, 24, 13	4.7 nanograms (ng)/milliliter (mL)	Standard Deviation 4.91
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	17.0 nanograms (ng)/milliliter (mL)	Standard Deviation 9.89
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, 3 hr PoD, n=23, 27, 27, 24, 14	39.2 nanograms (ng)/milliliter (mL)	Standard Deviation 44.59
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, 3 hr PoD, n=23, 27, 27, 24, 14	3.6 nanograms (ng)/milliliter (mL)	Standard Deviation 4.55
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	12.9 nanograms (ng)/milliliter (mL)	Standard Deviation 8.32
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	16.3 nanograms (ng)/milliliter (mL)	Standard Deviation 57.24
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, 2 hr PoD, n=23, 27, 27, 24, 13	3.6 nanograms (ng)/milliliter (mL)	Standard Deviation 4.5
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	6.7 nanograms (ng)/milliliter (mL)	Standard Deviation 5.51
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, 3 hr PoD, n=23, 27, 27, 24, 14	5.1 nanograms (ng)/milliliter (mL)	Standard Deviation 5.18
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, 1 hr PoD, n=23, 27, 27, 24, 13	4.0 nanograms (ng)/milliliter (mL)	Standard Deviation 6.77
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	4.5 nanograms (ng)/milliliter (mL)	Standard Deviation 4.16
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, 1 hr PoD, n=23, 27, 27, 24, 13	3.8 nanograms (ng)/milliliter (mL)	Standard Deviation 4.88
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, PrD, n=23, 28, 27, 23, 14	7.3 nanograms (ng)/milliliter (mL)	Standard Deviation 7.34
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	3.3 nanograms (ng)/milliliter (mL)	Standard Deviation 3.15
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	3.2 nanograms (ng)/milliliter (mL)	Standard Deviation 2.35
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, PrD, n=23, 28, 27, 23, 14	3.2 nanograms (ng)/milliliter (mL)	Standard Deviation 4.97
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	4.5 nanograms (ng)/milliliter (mL)	Standard Deviation 3.5
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, 1 hr PoD, n=23, 27, 27, 24, 13	2.7 nanograms (ng)/milliliter (mL)	Standard Deviation 3.6
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	8.1 nanograms (ng)/milliliter (mL)	Standard Deviation 23.76
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, 2 hr PoD, n=23, 27, 27, 24, 13	3.6 nanograms (ng)/milliliter (mL)	Standard Deviation 4.36
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, 2 hr PoD, n=23, 27, 27, 24, 13	4.5 nanograms (ng)/milliliter (mL)	Standard Deviation 4.96
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	14.7 nanograms (ng)/milliliter (mL)	Standard Deviation 10.02
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, 3 hr PoD, n=23, 27, 27, 24, 14	5.0 nanograms (ng)/milliliter (mL)	Standard Deviation 5.26
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, PrD, n=23, 28, 27, 23, 14	6.0 nanograms (ng)/milliliter (mL)	Standard Deviation 8.08
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, 3 hr PoD, n=23, 27, 27, 24, 14	2.2 nanograms (ng)/milliliter (mL)	Standard Deviation 2.22
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	4.1 nanograms (ng)/milliliter (mL)	Standard Deviation 4.47
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, 2 hr PoD, n=23, 27, 27, 24, 13	1.9 nanograms (ng)/milliliter (mL)	Standard Deviation 2.09
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	2.6 nanograms (ng)/milliliter (mL)	Standard Deviation 3.81
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	4.6 nanograms (ng)/milliliter (mL)	Standard Deviation 10.49
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, 1 hr PoD, n=23, 27, 27, 24, 13	1.0 nanograms (ng)/milliliter (mL)	Standard Deviation 1.34
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	1.9 nanograms (ng)/milliliter (mL)	Standard Deviation 3.21
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, PrD, n=23, 28, 27, 23, 14	1.2 nanograms (ng)/milliliter (mL)	Standard Deviation 2.03
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	1.5 nanograms (ng)/milliliter (mL)	Standard Deviation 2.46
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	4.1 nanograms (ng)/milliliter (mL)	Standard Deviation 3.41
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	1.4 nanograms (ng)/milliliter (mL)	Standard Deviation 1.49
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, PrD, n=23, 28, 27, 23, 14	0.5 nanograms (ng)/milliliter (mL)	Standard Deviation 1.05
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	1.8 nanograms (ng)/milliliter (mL)	Standard Deviation 1.86
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, 1 hr PoD, n=23, 27, 27, 24, 13	1.3 nanograms (ng)/milliliter (mL)	Standard Deviation 1.73
GSK1278863 4 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	2.7 nanograms (ng)/milliliter (mL)	Standard Deviation 2.41
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	1.9 nanograms (ng)/milliliter (mL)	Standard Deviation 1.52
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	7.7 nanograms (ng)/milliliter (mL)	Standard Deviation 18.46
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	8.7 nanograms (ng)/milliliter (mL)	Standard Deviation 19.85
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	5.6 nanograms (ng)/milliliter (mL)	Standard Deviation 11.75
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	4.4 nanograms (ng)/milliliter (mL)	Standard Deviation 9.19
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, PrD, n=23, 28, 27, 23, 14	0.9 nanograms (ng)/milliliter (mL)	Standard Deviation 2.82
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, 1 hr PoD, n=23, 27, 27, 24, 13	88.2 nanograms (ng)/milliliter (mL)	Standard Deviation 153.06
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, 2 hr PoD, n=23, 27, 27, 24, 13	62.8 nanograms (ng)/milliliter (mL)	Standard Deviation 85.37
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, 3 hr PoD, n=23, 27, 27, 24, 14	44.1 nanograms (ng)/milliliter (mL)	Standard Deviation 70.53
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	18.5 nanograms (ng)/milliliter (mL)	Standard Deviation 13.72
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	10.3 nanograms (ng)/milliliter (mL)	Standard Deviation 8.55
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	7.4 nanograms (ng)/milliliter (mL)	Standard Deviation 6.44
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	5.3 nanograms (ng)/milliliter (mL)	Standard Deviation 4.86
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, PrD, n=23, 28, 27, 23, 14	4.1 nanograms (ng)/milliliter (mL)	Standard Deviation 5.84
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, 1 hr PoD, n=23, 27, 27, 24, 13	4.3 nanograms (ng)/milliliter (mL)	Standard Deviation 4.9
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, 2 hr PoD, n=23, 27, 27, 24, 13	6.5 nanograms (ng)/milliliter (mL)	Standard Deviation 6.93
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, 3 hr PoD, n=23, 27, 27, 24, 14	7.3 nanograms (ng)/milliliter (mL)	Standard Deviation 6.69
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	5.7 nanograms (ng)/milliliter (mL)	Standard Deviation 6.31
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	3.5 nanograms (ng)/milliliter (mL)	Standard Deviation 4.55
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	2.7 nanograms (ng)/milliliter (mL)	Standard Deviation 3.58
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	1.9 nanograms (ng)/milliliter (mL)	Standard Deviation 2.85
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, PrD, n=23, 28, 27, 23, 14	0.7 nanograms (ng)/milliliter (mL)	Standard Deviation 1.28
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, 1 hr PoD, n=23, 27, 27, 24, 13	2.7 nanograms (ng)/milliliter (mL)	Standard Deviation 3.97
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, 2 hr PoD, n=23, 27, 27, 24, 13	5.0 nanograms (ng)/milliliter (mL)	Standard Deviation 5.82
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, 3 hr PoD, n=23, 27, 27, 24, 14	5.7 nanograms (ng)/milliliter (mL)	Standard Deviation 5.28
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	6.6 nanograms (ng)/milliliter (mL)	Standard Deviation 4.16
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	3.7 nanograms (ng)/milliliter (mL)	Standard Deviation 2.6
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	2.6 nanograms (ng)/milliliter (mL)	Standard Deviation 1.94
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, PrD, n=23, 28, 27, 23, 14	2.3 nanograms (ng)/milliliter (mL)	Standard Deviation 2.09
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, 1 hr PoD, n=23, 27, 27, 24, 13	1.4 nanograms (ng)/milliliter (mL)	Standard Deviation 1.22
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, 2 hr PoD, n=23, 27, 27, 24, 13	1.8 nanograms (ng)/milliliter (mL)	Standard Deviation 1.72
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, 3 hr PoD, n=23, 27, 27, 24, 14	1.9 nanograms (ng)/milliliter (mL)	Standard Deviation 1.53
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	6.9 nanograms (ng)/milliliter (mL)	Standard Deviation 4.52
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	4.0 nanograms (ng)/milliliter (mL)	Standard Deviation 2.97
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	2.9 nanograms (ng)/milliliter (mL)	Standard Deviation 2.3
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	2.1 nanograms (ng)/milliliter (mL)	Standard Deviation 1.99
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, PrD, n=23, 28, 27, 23, 14	1.4 nanograms (ng)/milliliter (mL)	Standard Deviation 1.93
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, 1 hr PoD, n=23, 27, 27, 24, 13	1.6 nanograms (ng)/milliliter (mL)	Standard Deviation 1.81
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, 2 hr PoD, n=23, 27, 27, 24, 13	2.9 nanograms (ng)/milliliter (mL)	Standard Deviation 3.28
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, 3 hr PoD, n=23, 27, 27, 24, 14	3.3 nanograms (ng)/milliliter (mL)	Standard Deviation 2.89
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	22.2 nanograms (ng)/milliliter (mL)	Standard Deviation 14.71
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	11.8 nanograms (ng)/milliliter (mL)	Standard Deviation 8.49
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	8.1 nanograms (ng)/milliliter (mL)	Standard Deviation 5.74
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	5.9 nanograms (ng)/milliliter (mL)	Standard Deviation 4.66
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, PrD, n=23, 28, 27, 23, 14	7.9 nanograms (ng)/milliliter (mL)	Standard Deviation 7.37
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, 1 hr PoD, n=23, 27, 27, 24, 13	4.7 nanograms (ng)/milliliter (mL)	Standard Deviation 4.18
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, 2 hr PoD, n=23, 27, 27, 24, 13	4.8 nanograms (ng)/milliliter (mL)	Standard Deviation 4.08
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, 3 hr PoD, n=23, 27, 27, 24, 14	5.0 nanograms (ng)/milliliter (mL)	Standard Deviation 4.64
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	23.1 nanograms (ng)/milliliter (mL)	Standard Deviation 15.22
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	13.1 nanograms (ng)/milliliter (mL)	Standard Deviation 9.73
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	9.3 nanograms (ng)/milliliter (mL)	Standard Deviation 7.37
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	6.7 nanograms (ng)/milliliter (mL)	Standard Deviation 5.5
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, PrD, n=23, 28, 27, 23, 14	6.7 nanograms (ng)/milliliter (mL)	Standard Deviation 6.74
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, 1 hr PoD, n=23, 27, 27, 24, 13	5.0 nanograms (ng)/milliliter (mL)	Standard Deviation 4.71
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, 2 hr PoD, n=23, 27, 27, 24, 13	6.8 nanograms (ng)/milliliter (mL)	Standard Deviation 6.54
GSK1278863 6 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, 3 hr PoD, n=23, 27, 27, 24, 14	7.4 nanograms (ng)/milliliter (mL)	Standard Deviation 6.43
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	12.7 nanograms (ng)/milliliter (mL)	Standard Deviation 28.6
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, PrD, n=23, 28, 27, 23, 14	9.3 nanograms (ng)/milliliter (mL)	Standard Deviation 10.95
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, 3 hr PoD, n=23, 27, 27, 24, 14	3.8 nanograms (ng)/milliliter (mL)	Standard Deviation 3.1
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, PrD, n=23, 28, 27, 23, 14	1.6 nanograms (ng)/milliliter (mL)	Standard Deviation 3.8
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	10.9 nanograms (ng)/milliliter (mL)	Standard Deviation 6.37
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, 1 hr PoD, n=23, 27, 27, 24, 13	6.2 nanograms (ng)/milliliter (mL)	Standard Deviation 8.65
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, 1 hr PoD, n=23, 27, 27, 24, 13	5.6 nanograms (ng)/milliliter (mL)	Standard Deviation 7.48
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, PrD, n=23, 28, 27, 23, 14	1.3 nanograms (ng)/milliliter (mL)	Standard Deviation 4.09
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, 3 hr PoD, n=23, 27, 27, 24, 14	8.2 nanograms (ng)/milliliter (mL)	Standard Deviation 6.52
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	20.1 nanograms (ng)/milliliter (mL)	Standard Deviation 12.32
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, 2 hr PoD, n=23, 27, 27, 24, 13	6.1 nanograms (ng)/milliliter (mL)	Standard Deviation 8.21
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	1.9 nanograms (ng)/milliliter (mL)	Standard Deviation 1.92
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	4.1 nanograms (ng)/milliliter (mL)	Standard Deviation 3.73
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, 3 hr PoD, n=23, 27, 27, 24, 14	5.5 nanograms (ng)/milliliter (mL)	Standard Deviation 5.38
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, 2 hr PoD, n=23, 27, 27, 24, 13	8.1 nanograms (ng)/milliliter (mL)	Standard Deviation 10.33
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, PrD, n=23, 28, 27, 23, 14	7.8 nanograms (ng)/milliliter (mL)	Standard Deviation 11.14
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, 3 hr PoD, n=23, 27, 27, 24, 14	71.2 nanograms (ng)/milliliter (mL)	Standard Deviation 110.91
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	25.4 nanograms (ng)/milliliter (mL)	Standard Deviation 53.37
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	24.5 nanograms (ng)/milliliter (mL)	Standard Deviation 18.27
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	11.3 nanograms (ng)/milliliter (mL)	Standard Deviation 25.36
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, 2 hr PoD, n=23, 27, 27, 24, 13	82.7 nanograms (ng)/milliliter (mL)	Standard Deviation 117.97
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, 3 hr PoD, n=23, 27, 27, 24, 14	8.4 nanograms (ng)/milliliter (mL)	Standard Deviation 6.86
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	25.4 nanograms (ng)/milliliter (mL)	Standard Deviation 14.25
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, 1 hr PoD, n=23, 27, 27, 24, 13	2.0 nanograms (ng)/milliliter (mL)	Standard Deviation 3.58
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	6.9 nanograms (ng)/milliliter (mL)	Standard Deviation 4.25
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, 1 hr PoD, n=23, 27, 27, 24, 13	5.0 nanograms (ng)/milliliter (mL)	Standard Deviation 8.1
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, 1 hr PoD, n=23, 27, 27, 24, 13	58.5 nanograms (ng)/milliliter (mL)	Standard Deviation 85.91
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, 2 hr PoD, n=23, 27, 27, 24, 13	8.5 nanograms (ng)/milliliter (mL)	Standard Deviation 10.83
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	2.1 nanograms (ng)/milliliter (mL)	Standard Deviation 1.23
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	2.2 nanograms (ng)/milliliter (mL)	Standard Deviation 1.38
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	13.1 nanograms (ng)/milliliter (mL)	Standard Deviation 9.5
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	2.9 nanograms (ng)/milliliter (mL)	Standard Deviation 1.68
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	13.9 nanograms (ng)/milliliter (mL)	Standard Deviation 7.66
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, PrD, n=23, 28, 27, 23, 14	2.6 nanograms (ng)/milliliter (mL)	Standard Deviation 2.87
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, 1 hr PoD, n=23, 27, 27, 24, 13	3.4 nanograms (ng)/milliliter (mL)	Standard Deviation 5.88
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	7.2 nanograms (ng)/milliliter (mL)	Standard Deviation 6.57
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	4.1 nanograms (ng)/milliliter (mL)	Standard Deviation 2.15
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, PrD, n=23, 28, 27, 23, 14	4.6 nanograms (ng)/milliliter (mL)	Standard Deviation 9.29
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, 1 hr PoD, n=23, 27, 27, 24, 13	1.8 nanograms (ng)/milliliter (mL)	Standard Deviation 2.12
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	3.1 nanograms (ng)/milliliter (mL)	Standard Deviation 1.95
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	9.0 nanograms (ng)/milliliter (mL)	Standard Deviation 7.05
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	7.6 nanograms (ng)/milliliter (mL)	Standard Deviation 4.3
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, 2 hr PoD, n=23, 27, 27, 24, 13	3.5 nanograms (ng)/milliliter (mL)	Standard Deviation 4.69
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, 2 hr PoD, n=23, 27, 27, 24, 13	2.2 nanograms (ng)/milliliter (mL)	Standard Deviation 2.53
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	2.7 nanograms (ng)/milliliter (mL)	Standard Deviation 2.44
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	5.4 nanograms (ng)/milliliter (mL)	Standard Deviation 3.63
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, PrD, n=23, 28, 27, 23, 14	7.9 nanograms (ng)/milliliter (mL)	Standard Deviation 30.99
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, 3 hr PoD, n=23, 27, 27, 24, 14	2.1 nanograms (ng)/milliliter (mL)	Standard Deviation 1.66
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	19.9 nanograms (ng)/milliliter (mL)	Standard Deviation 42.65
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	6.3 nanograms (ng)/milliliter (mL)	Standard Deviation 4.9
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, 3 hr PoD, n=23, 27, 27, 24, 14	6.5 nanograms (ng)/milliliter (mL)	Standard Deviation 5.05
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	4.5 nanograms (ng)/milliliter (mL)	Standard Deviation 2.7
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	7.4 nanograms (ng)/milliliter (mL)	Standard Deviation 4.51
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, 2 hr PoD, n=23, 27, 27, 24, 13	6.3 nanograms (ng)/milliliter (mL)	Standard Deviation 8.04
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	9.6 nanograms (ng)/milliliter (mL)	Standard Deviation 5.5
GSK1278863 8 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	8.0 nanograms (ng)/milliliter (mL)	Standard Deviation 4.87
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	9.0 nanograms (ng)/milliliter (mL)	Standard Deviation 18.8
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, 1 hr PoD, n=23, 27, 27, 24, 13	1.0 nanograms (ng)/milliliter (mL)	Standard Deviation 1.34
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	9.9 nanograms (ng)/milliliter (mL)	Standard Deviation 9.05
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	4.9 nanograms (ng)/milliliter (mL)	Standard Deviation 4.05
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, PrD, n=23, 28, 27, 23, 14	0.7 nanograms (ng)/milliliter (mL)	Standard Deviation 1.84
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	11.2 nanograms (ng)/milliliter (mL)	Standard Deviation 33.59
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	2.5 nanograms (ng)/milliliter (mL)	Standard Deviation 1.78
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	1.9 nanograms (ng)/milliliter (mL)	Standard Deviation 2.21
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	2.3 nanograms (ng)/milliliter (mL)	Standard Deviation 1.42
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	1.7 nanograms (ng)/milliliter (mL)	Standard Deviation 1.68
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, PrD, n=23, 28, 27, 23, 14	1.2 nanograms (ng)/milliliter (mL)	Standard Deviation 2.67
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	3.7 nanograms (ng)/milliliter (mL)	Standard Deviation 4.61
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	8.9 nanograms (ng)/milliliter (mL)	Standard Deviation 7.79
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, 1 hr PoD, n=23, 27, 27, 24, 13	1.0 nanograms (ng)/milliliter (mL)	Standard Deviation 1.45
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	5.2 nanograms (ng)/milliliter (mL)	Standard Deviation 4.66
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	4.6 nanograms (ng)/milliliter (mL)	Standard Deviation 6.87
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, 2 hr PoD, n=23, 27, 27, 24, 13	2.1 nanograms (ng)/milliliter (mL)	Standard Deviation 1.79
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W20, 3 hr PoD, n=23, 27, 27, 24, 14	2.8 nanograms (ng)/milliliter (mL)	Standard Deviation 2.34
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, 3 hr PoD, n=23, 27, 27, 24, 14	6.1 nanograms (ng)/milliliter (mL)	Standard Deviation 4.92
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0.02
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, 2 hr PoD, n=23, 27, 27, 24, 13	4.9 nanograms (ng)/milliliter (mL)	Standard Deviation 4.08
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	29.1 nanograms (ng)/milliliter (mL)	Standard Deviation 24.55
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, 1 hr PoD, n=23, 27, 27, 24, 13	2.6 nanograms (ng)/milliliter (mL)	Standard Deviation 3.64
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, PrD, n=23, 28, 27, 23, 14	6.2 nanograms (ng)/milliliter (mL)	Standard Deviation 8.78
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	17.3 nanograms (ng)/milliliter (mL)	Standard Deviation 16.03
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W20, PrD, n=23, 28, 27, 23, 14	3.5 nanograms (ng)/milliliter (mL)	Standard Deviation 6.69
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	8.0 nanograms (ng)/milliliter (mL)	Standard Deviation 16.92
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	10.1 nanograms (ng)/milliliter (mL)	Standard Deviation 10.61
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	6.6 nanograms (ng)/milliliter (mL)	Standard Deviation 5.72
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	8.7 nanograms (ng)/milliliter (mL)	Standard Deviation 8.72
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	7.2 nanograms (ng)/milliliter (mL)	Standard Deviation 6.97
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, 3 hr PoD, n=23, 27, 27, 24, 14	6.5 nanograms (ng)/milliliter (mL)	Standard Deviation 5.14
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, PrD, n=23, 28, 27, 23, 14	7.2 nanograms (ng)/milliliter (mL)	Standard Deviation 10.04
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	13.1 nanograms (ng)/milliliter (mL)	Standard Deviation 12.44
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, 1 hr PoD, n=23, 27, 27, 24, 13	4.5 nanograms (ng)/milliliter (mL)	Standard Deviation 5.44
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	21.3 nanograms (ng)/milliliter (mL)	Standard Deviation 17.34
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, 1 hr PoD, n=23, 27, 27, 24, 13	4.0 nanograms (ng)/milliliter (mL)	Standard Deviation 4.8
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, 2 hr PoD, n=23, 27, 27, 24, 13	4.4 nanograms (ng)/milliliter (mL)	Standard Deviation 4.41
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2391220, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	7.9 nanograms (ng)/milliliter (mL)	Standard Deviation 5.75
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531401, W20, 3 hr PoD, n=23, 27, 27, 24, 14	4.5 nanograms (ng)/milliliter (mL)	Standard Deviation 4.28
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, 3 hr PoD, n=23, 27, 27, 24, 14	65.8 nanograms (ng)/milliliter (mL)	Standard Deviation 100.8
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, 2 hr PoD, n=23, 27, 27, 24, 13	63.3 nanograms (ng)/milliliter (mL)	Standard Deviation 102.15
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	28.8 nanograms (ng)/milliliter (mL)	Standard Deviation 21.46
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, 1 hr PoD, n=23, 27, 27, 24, 13	65.2 nanograms (ng)/milliliter (mL)	Standard Deviation 127.21
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 9-15 hr PoD, n=35, 36, 36, 35, 15	2.7 nanograms (ng)/milliliter (mL)	Standard Deviation 2.04
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 8-14 hr PoD, n=35, 37, 36, 35, 15	2.9 nanograms (ng)/milliliter (mL)	Standard Deviation 2.24
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, PrD, n=23, 28, 27, 23, 14	2.2 nanograms (ng)/milliliter (mL)	Standard Deviation 2.87
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	5.4 nanograms (ng)/milliliter (mL)	Standard Deviation 4.1
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W4, 7-13 hr PoD, n=36, 37, 35, 35, 15	17.4 nanograms (ng)/milliliter (mL)	Standard Deviation 14.72
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, 1 hr PoD, n=23, 27, 27, 24, 13	1.4 nanograms (ng)/milliliter (mL)	Standard Deviation 1.57
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W4, 6-12 hr PoD, n=36, 37, 37, 35, 15	9.0 nanograms (ng)/milliliter (mL)	Standard Deviation 6.19
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK1278863, W20, PrD, n=23, 28, 27, 23, 14	6.6 nanograms (ng)/milliliter (mL)	Standard Deviation 20.22
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, 2 hr PoD, n=23, 27, 27, 24, 13	1.6 nanograms (ng)/milliliter (mL)	Standard Deviation 1.37
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2506102, W20, 3 hr PoD, n=23, 27, 27, 24, 14	1.7 nanograms (ng)/milliliter (mL)	Standard Deviation 1.42
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, 3 hr PoD, n=23, 27, 27, 24, 14	5.0 nanograms (ng)/milliliter (mL)	Standard Deviation 4.43
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531403, W20, 2 hr PoD, n=23, 27, 27, 24, 13	5.5 nanograms (ng)/milliliter (mL)	Standard Deviation 4.58
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2531398, D1, PrD, n=39, 40, 39, 40, 18	0.0 nanograms (ng)/milliliter (mL)	Standard Deviation 0
GSK1278863 10 mg	Population Plasma PK Parameters of GSK1278863 and Metabolites	GSK2487818, W20, 2 hr PoD, n=23, 27, 27, 24, 13	3.7 nanograms (ng)/milliliter (mL)	Standard Deviation 3.28

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026

Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Change From Baseline in Hemoglobin (Hgb) at Week 4

Change From Baseline in Ferritin at Week 24

Change From Baseline in Hematocrit at Week 24

Change From Baseline in Red Blood Cells at Week 24

Change From Baseline in Reticulocyte Count at Week 24

Change From Baseline in Reticulocyte Hemoglobin at Week 24

Change From Baseline in Total Iron at Week 24

Change From Baseline in Total Iron Binding Capacity at Week 24

Change From Baseline in Transferrin at Week 24

Hgb Concentration at Week 24

Maximum Observed Change From Baseline in Erythropoietin (EPO)

Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)

Number of Participants Reaching Pre-defined Hgb Stopping Criteria

Number of Participants With Hgb in the Target Range at Week 24

Percentage of Time Within, Below, and Above Hgb Target Range Between Weeks 20 and 24

Percent Change From Baseline in Hepcidin at Week 24

Percent Change From Baseline in Transferrin Saturation at Week 24

Population Plasma PK Parameters of GSK1278863 and Metabolites